Level Biotechnology (3118) reported revenue of NT$46.3 million for Oct 2026, -8.2% year on year and -27.4% from the previous month. Revenue for Jan–Oct 2026 was NT$553.6 million (-7.6% year on year).
In Oct 2026, it ranked No. 102 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$46.3 million | -8.2% | -27.4% |
| Sep 2026 | NT$63.7 million | -9.2% | +12.2% |
| Aug 2026 | NT$56.8 million | -16.2% | -13.3% |
| Jul 2026 | NT$65.5 million | +5.5% | +19.7% |
| Jun 2026 | NT$54.7 million | -3.6% | +10.8% |
| May 2026 | NT$49.4 million | -9.1% | -15.2% |
| Apr 2026 | NT$58.2 million | -3.6% | -17.2% |
| Mar 2026 | NT$70.3 million | +0.7% | +124.3% |
| Feb 2026 | NT$31.3 million | -48.6% | -45.2% |
| Jan 2026 | NT$57.2 million | +24.2% | -27.3% |
| Dec 2025 | NT$78.7 million | +8.7% | +33.5% |
| Nov 2025 | NT$58.9 million | -12.0% | +16.8% |
| Oct 2025 | NT$50.4 million | -22.9% | -28.1% |
| Sep 2025 | NT$70.2 million | +24.0% | +3.5% |
| Aug 2025 | NT$67.8 million | +3.8% | +9.2% |
| Jul 2025 | NT$62.1 million | +3.0% | +9.4% |
| Jun 2025 | NT$56.8 million | -6.4% | +4.4% |
| May 2025 | NT$54.4 million | -3.5% | -10.0% |
| Apr 2025 | NT$60.4 million | +23.0% | -13.5% |
| Mar 2025 | NT$69.8 million | -9.5% | +14.5% |
| Feb 2025 | NT$61 million | +46.5% | +32.4% |
| Jan 2025 | NT$46.1 million | -22.6% | -36.4% |
| Dec 2024 | NT$72.4 million | +6.5% | +8.2% |
| Nov 2024 | NT$66.9 million | +9.1% | +2.3% |
| Oct 2024 | NT$65.4 million | +8.7% | +15.6% |
Jan–Oct 2026 cumulative: NT$553.6 million (-7.6% YoY)
Other Biotech & Medical companies
Compare with peers: Level Biotechnology vs PEC / Level Biotechnology vs Lotus Pharm / Level Biotechnology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16